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Abstract
Background: Bisphosphonates and parathyroid hormone (PTH) represent the antiresorptive and anabolic classes of drugs
for osteoporosis treatment. Bone mineral density (BMD) is an essential parameter for the evaluation of anti-osteoporotic
drugs. The aim of this study was to evaluate the effects of PTH versus bisphosphonates on BMD for the treatment of
osteoporosis.
Methods/Principal Findings: We performed a literature search to identify studies that investigated the effects of PTH versus
bisphosphonates treatment on BMD. A total of 7 articles were included in this study, representing data on 944 subjects. The
pooled data showed that the percent change of increased BMD in the spine is higher with PTH compared to
bisphosphonates (WMD=5.90, 95% CI: 3.69–8.10, p,0.01,). In the hip, high dose (40 mg) PTH (1–34) showed significantly
higher increments of BMD compared to alendronate (femoral neck: WMD=5.67, 95% CI: 3.47–7.87, p,0.01; total hip:
WMD=2.40, 95%CI: 0.49–4.31, p,0.05). PTH treatment has yielded significantly higher increments than bisphosphonates
with a duration of over 12 months (femoral neck: WMD=5.67, 95% CI: 3.47–7.86, p,0.01; total hip: WMD=2.40, 95% CI:
0.49–4.31, P,0.05) and significantly lower increments at 12 months (femoral neck: WMD=21.05, 95% CI: 22.26–0.16,
p,0.01; total hip: WMD: 21.69, 95% CI: 23.05–0.34, p,0.05). In the distal radius, a reduction in BMD was significant
between PTH and alendronate treatment. (WMD=23.68, 95% CI: 25.57–1.79, p,0.01).
Discussion: Our results demonstrated that PTH significantly increased lumbar spine BMD as compared to treatment with
bisphosphonates and PTH treatment induced duration- and dose-dependent increases in hip BMD as compared to
bisphosphonates treatment. This study has also disclosed that for the distal radius, BMD was significantly lower from PTH
treatment than alendronate treatment.
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Introduction
Osteoporosis is a common skeletal disease characterized by low
bone mass and deterioration in bone micro-architecture, which
induces bone fragility and increased risk of fracture [1]. Increasing
bone mass and improving bone architecture and strength reduces
skeletal fragility and the risk of fracture and are the optimal
treatments for osteoporosis.
Antiresorptive agents, such as bisphosphonates, are the most
widely used group of drugs for osteoporosis treatment [2,3,4].
Bisphosphonates directly reduce the number of active osteoclasts
by inhibiting their recruitment and also by inhibiting the
osteoclast-stimulating activity of osteoblasts [5,6]. bisphosphonate
therapy normalizes bone turnover, reduces the number of bone
remodeling units, restores the balance of bone remodeling,
prevents bone loss and deterioration of bone structure and reduces
fracture risk in patients with osteoporosis [6,7,8].
Parathyroid hormone (PTH) is used clinically as an anabolic
agent [9,10,11,12,13]. Two forms of recombinant human PTH
have been evaluated: teriparatide, the 34 residue amino-terminal
fragment of human PTH (1–34) and the intact 84-amino acid form
of PTH (1–84), which is marketed as PreotactH [14]. PTH directly
increases osteoblast production rate and inhibits apoptosis of
osteoblasts, thereby leading to a rapid increase in skeletal mass as
well as improvement of bone micro-architecture and strength [15].
A decrease in bone mineral density (BMD) is a significant risk
factor for fracture and is of similar importance in both women and
men [16,17]. The measurement of BMD is a major determinant of
fracture and an essential parameter for the evaluation of anti-
osteoporotic drugs used in clinical therapy. As more studies
comparing the effects of PTH and bisphosphonates on BMD in
patients with osteoporosis are now becoming available, we decided
to perform a meta-analysis on the effects of PTH and
bisphosphonates on BMD for the treatment of osteoporosis. Our
main goal was to study the effects of PTH and bisphosphonates on
BMD separately at various skeletal sites (lumbar spine, total hip,
femoral neck and distal radius).
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Search Strategy
This meta-analysis followed the PRISMA statement guidelines
[18]. A literature search was performed on August 17, 2010 and an
updated search was performed on 14 April 2011 using the phrase,
‘‘parathyroid hormone AND bisphosphonate AND osteoporosis’’
with the limits ‘‘humans’’ and ‘‘randomized controlled trial’’. A
second search was performed using the phrase, ‘‘parathyroid
hormone AND bisphosphonate AND bone mineral’’ with the limits
‘‘humans’’and ‘‘randomized controlled trial’’usingPubMed (1990–
2010), Ovid’s MEDLINE (1990–2010), MEDLINE In Process &.
Other Non-Indexed Citations (1990-2010), Web of Knowledge and
EMBASE (1991–2010). Further searches using the same keywords
and limitations did not provide additional references. We also
performed a search of the Cochrane Central Register of Controlled
Trials and a conference abstract search of the Journal of Bone and
Mineral Research. Review articles were also scanned to find
additional eligible studies. In addition, reference lists of all original
articles and previous systematic reviews were hand searched for
other relevant papers. The searches were not restricted to English
language literature. Duplicates were removed. Information was
carefully extracted from all eligible publications independently by
two of the authors of the present study (LS and XX). Differences in
theextractionofdatawereinspectedbya thirdinvestigator(CL).All
the searched studies were retrieved and their references were
checked for other relevant publications. The search results were
then screened on the basis of the following inclusion criteria: (a)
randomized controlled studies with a duration of at least 6 months,
(b) The active treatment arm of the study had to include PTH and
bisphosphonate, and (c) Studies on patients with postmenopausal or
gonadal osteoporosis. Exclusion criteria included non-randomized
trialsorduration of less than 6 monthsand studies on any secondary
osteoporosis (for example, glucocorticoid-induced). Reports were
excluded if the subjects had prior treatment with PTH or a PTH
analogue or treatment with bisphosphonates within the previous 12
months. Both area BMD data measured by dual X-ray absorpti-
ometry (DXA) and volumetric BMD data measured by quantitative
controlled trials were eligible. The Jadad scale was used to assess the
qualityof included randomly controlled trials(RCTs), where a score
of ,3 indicated low quality [19].
Statistical analysis
Changes in BMD values were expressed in percent change vs.
baseline for both PTH and bisphosphonate treatment groups. We
calculated the weighted mean differences (WMD) for percent
changes in BMD. We conducted a random-effects model meta-
analysis for heterogeneous outcomes and a fixed-effects model
meta-analysis for homogeneous outcomes. The pooled analyses
were performed using the Stata/SE 10.0 program for Windows
(Stata Corporation, College Station, TX, USA). Statistical
heterogeneity was investigated using the x
2 test and I
2 statistic
(I
2 represents the percentage of variability due to between-study
variability). Funnel plots and the Egger’s tests were used to
estimate possible publication bias. A sensitivity analysis was
conducted using the trim and fill method, to detect possible
publication bias. A p-value less than 0.05 was considered to be
statistically significant.
Results
Selected studies and characteristics
A total of 782 potentially relevant citations were identified and
screened, of which only 7 published RCTs met the inclusion
criteria and were selected for this meta-analysis [10,20,21,22,
23,24,25] (Figure 1). The main characteristics of the 7 studies are
shown in Table 1. The level of evidence for each article was
graded from scores 3 to 5 according to the Jadad quality score. A
total of 944 patients, 896 women and 48 men were included in this
analysis. Six trials involved postmenopausal women with osteopo-
rosis [10,20,21,22,24,25] and one trial involved osteoporotic men
[23]. Of the 7 included trials, 5 had demonstrated the effects of
alendronate [10,20,22,23,24], one showed results from risedronate
[21] and the last showed the effects of zoledronic acid [25].
Allocation concealment was adequately reported in 4 trials
[19,20,22,24] and unclear in the remaining trials. Four trials were
double-blind or partially double-blind [10,22,24,25].
Effects of PTH versus bisphosphonates on spinal BMD
All of the 7 RCTs studied lumbar spine areal BMD. Finkelstein
et al. [23] reported BMD data in both posteroanterior spine and
lateral spine. The pooled data showed that the percent change of
increased BMD in the spine is higher with PTH in comparison to
treatment with bisphosphonates after 12–30 months (WMD=
5.90, 95% CI: 3.69–8.10, p,0.01, n=953). These estimates were
heterogeneous. To explore this heterogeneity, we assessed the data
within subgroups based on the gender of the participants and the
type of agent used. For women, the pooled data from 6 studies
showed that increases in BMD was higher in PTH treatment than
that of bisphosphonates (WMD=4.27, 95% CI: 2.46–6.08,
p,0.01; n=865). Whereas for men, Finkelstein et al. [23]
reported that PTH treatment resulted in statistically significant
increases in both posteroanterior spine and lateral spine BMD
values as compared to that of alendronate. Comparing PTH
treatment to alendronate, the increase in spine BMD was
significantly higher in the PTH group (WMD=7.42, 95% CI:
4.21–10.62, p,0.01; five studies, n=649). Comparing PTH values
to other types of bisphosphonates, the results were consistent
(WMD=2.74, 95% CI: 1.68–3.74, p,0.01; two studies, n=304).
The effects of 20–40 mg of PTH (1–34) compared to those of the
bisphosphonate groups showed a significantly higher increase in
BMD values (WMD=4.41, 95% CI: 3.60–5.21, p,0.01; six
studies, n=774). Heterogeneity remained in the above analysis.
To further explore this heterogeneity, subgroup analysis showed
that the effects of both 20 mg and 40 mg of PTH (1–34) treatment
increased lumbar spine BMD values significantly higher than
bisphosphonates (WMD=3.31, 95% CI: 2.42–4.21, p,0.01; three
studies, n=491; WMD=8.92, 95% CI: 7.10–10.75, p,0.01;
three studies, n=283, respectively). Heterogeneity was not found
in both subgroups (Figure 2A). In addition, we also grouped the
studies on the basis of the duration of treatment. PTH treatment
has yielded consistently and significantly higher increments as
compared to the bisphosphonate groups (12 months: WMD=
3.00, 95% CI: 1.69–4.32, p,0.01; four studies, n=670; over 12
months: WMD=9.85, 95% CI: 6.70–13.01, p,0.01; three
studies, n=283) (Figure 2B). Heterogeneity was not found in
either duration subgroup. The shape of the funnel plot showed
slight asymmetry and the Egger’s test indicated publication bias
(P,0.05) (Figure 3A). We conducted a trim and fill method to
further investigate the publication bias. The imputed studies
produced a symmetrical funnel plot (Figure 3B) and the pooled
analysis incorporating the hypothetical studies continued to show
statistically significant higher increments in BMD values with PTH
treatment over those using bisphosphonates (WMD=3.48, 95%
CI: 1.09–5.88, p,0.01).
Four of the 6 RCTs reported volumetric BMD data of the
lumbar spine. The overall pooled results by random-effects
analysis showed that the increase was higher with PTH treatment
PTH versus Bisphosphonate on Bone Mineral Density
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Table 1. Basal characteristics of clinical trials enrolled in the analysis.
Author
(Ref.) Year
Gender
(F/M)
Number of
patients (PTH/
bisphosphonate)
Intervention
(calcium and/or vitamin D)
Duration
(months)
Outcomes measured:
Areal BMD, volumetric
BMD
Jadad
score [19]
Cosman
et al. [25]
2011 F 138 vs.137 20 mg PTH (1–34)/day + placebo
infusion of zoledronic acid vs. a single
intravenous infusion of zoledronic
acid 5 mg. No placebo PTH. All:
1000–1200 mg calcium/day +400–800
IU vitamin D/day
12 Areal BMD: lumbar spine,
total hip, femoral neck
3
Finkelstein
et al. [20]
2010 F 20 vs. 29 40 mg PTH (1–34)/day vs. alendronate
10 mg/day. No placebo PTH. All:
1000–1200 mg calcium/day
(diet or suppl.) +400 IU vitamin D/day
30 Areal BMD: lumbar spine,
total hip, femoral neck,
distal radius. Volumetric BMD:
lumbar spine.
3
Anastasilakis
et al. [21]
2008 F 22 vs. 22 35 mg Risedronate/week vs. 20 mg PTH
(1–34)/day. No placebo PTH. All: 500 mg
elemental calcium/day+400 IU vitamin D/day
12 Areal BMD: lumbar spine. 3
McClung
et al. [22]
2005 F 102 vs. 101 20 mg PTH (1–34)/day+oral placebo vs.
10 mg alendronate 10/day+placebo injection.
All: 1000 mg calcium/day (diet or suppl.)
+400 to 800 IU vitamin D/day
12 Areal BMD: lumbar spine
and femoral neck. Volumetric
BMD: lumbar spine
3
Finkelstein
et al. [23]
2003 M 20 vs. 28 40 mg PTH (1–34)/day vs. alendronate
10 mg/day. No placebo PTH. All: 1000 to
1200 mg calcium/day (diet or suppl.)
+400 IU vitamin D/day
30 Areal BMD: lumbar spine
(posteroanterior and lateral),
total hip, femoral neck,
distal radius. Volumetric BMD:
lumbar spine.
3
Black
et al. [10]
2003 F 119 vs. 60 100 mg PTH (1–84)/day vs. alendronate
10 mg/day. Placebo PTH All: 500 mg
calcium/day+400 IU vitamin D/day
12 Areal BMD: lumbar spine,
total hip, femoral neck,
distal radius . Volumetric
BMD: lumbar spine
4
Body
et al. [24]
2002 F 73 vs. 73 40 mg rPTH (1–34) +oral placebo vs.
alendronate+placebo inj. All: calcium
1000 mg/day+vitamin D 400
to 1200 IU/day
14 Areal BMD: lumbar spine,
total hip, femoral neck,
distal radius
4
doi:10.1371/journal.pone.0026267.t001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26267Figure 3. Funnel plot of all studies on the effects of PTH and bisphosphonates on spine BMD. A: Begg’s funnel plot with pseudo 95%
confidence limits. B: Filled funnel plot with pseudo 95% confidence limits. WMD, weighted mean difference; S.E., standard error.
doi:10.1371/journal.pone.0026267.g003
Figure 2. Assessment of the effects of PTH versus bisphosphonates on BMD of the lumbar spine. A: Subgrouped analysis of dosage of
PTH (1–34) versus bisphosphonates treatment on spinal BMD. B: Subgrouped analysis of the duration of PTH (1–34) versus bisphosphonates
treatment on spinal BMD. X: The study reported BMD data in lateral spine.
doi:10.1371/journal.pone.0026267.g002
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(95% CI: 13.81–52.12, p,0.01; four studies, n=325). This
comparison showed significant heterogeneity (Table 2). Funnel
plot and Egger’s test results did not reveal signs of publication bias
(plot not shown).
Effects of PTH versus alendronate on BMD of the hip
In this pooled analysis, the increases in the femoral neck BMD
values were not significant between PTH and bisphosphonate
treatments (WMD=2.24, 95% CI: 20.48–4.97, p=0.11,
n=824). In women, no significant difference was observed
between the PTH and bisphosphonate groups (WMD=1.54,
95% CI: 21.25–4.33, p=0.28; five studies, n=777). Nonetheless,
statistical heterogeneity was large both in overall pooled analysis
and in the analysis of women (I
2.80%, p,0.01). For men, there
was only one trial (n=47) that investigated the effects of 40 mg
PTH (1–34) versus 10 mg alendronate daily on the femoral neck
BMD during osteoporosis treatment [23]; therefore, we were
unable to estimate a pooled effect. A sensitivity analysis excluding
the trial using full-length PTH (1–84) [10] indicated that PTH (1–
34) increased femoral neck BMD with no significant difference to
the bisphosphonate group (WMD=3.09, 95%CI: 20.30–6.48,
p=0.07, five studies, n=645). Statistical heterogeneity was found
in the analysis (I
2=93%, p,0.01). We then grouped the studies on
the basis of the dose of PTH (1–34) used for treatment. 20 mgo f
PTH (1–34) yielded lower increments compared to bisphospho-
nates without statistical significance (WMD=20.78, 95% CI:
22.93–1.37, p=0.48; two studies, n=403), while 40 mg PTH (1–
34) showed significantly higher increments of BMD than
alendronate (WMD=5.67, 95% CI: 3.47–7.87, p,0.01 ; three
studies, n=242). Heterogeneity was found in the 20 mg treatment
subgroup (I
2=77.3%, p,0.05), but not in the 40 mg subgroup
(I
2=51.0%, p=0.13) (Figure 4A). In the grouped studies
comparing the duration of treatment, PTH treatment has yielded
significantly higher increments than bisphosphonates with a
duration of over 12 months (WMD=5.67, 95% CI: 3.47–7.86,
p,0.01; three studies, n=242), and significantly lower increments
at 12 months (WMD=21.05, 95% CI: 22.26–0.16, p,0.01;
three studies, n=682). Heterogeneity was not found in either of
the duration subgroups (I
2=51%, p=0.13; I
2=56%, p=0.09,
respectively) (Figure 4B). The shape of the funnel plot showed
slight asymmetry and the Egger’s test indicated publication bias
(p,0.05). The trimmed and filled funnel plot was symmetrical
(plot not shown). The pooled analysis, incorporating the two
hypothetical studies, continued to show statistically non-significant
increments of BMD between the PTH and bisphosphonate groups
(WMD=0.01, 95% CI: 22.84–2.84, p=0.10).
The pooled data showed there was no significant difference
between PTH and bisphosphonates in increasing total hip BMD
(WMD=0.59, 95% CI: 21.42–2.60, p=0.57, five studies,
n=683). For PTH (1–34) treatment, the pooled data showed that
BMD increase in the total hip was not significant as compared to
bisphosphonates (WMD=1.48, 95%CI: 20.91–3.87, p,0.05,
four studies, n=504). Heterogeneity was found among the studies.
A sensitivity analysis conducted by removing the 20 mg PTH study
[26] indicated that treatment with 40 mg of PTH (1–34) increased
total hip BMD significantly higher than alendronate treatment
(WMD=2.40, 95%CI: 0.49–4.31, p,0.05, three studies, n=242).
Heterogeneity was not found among these studies (I
2=52.8%,
p=0.12) (Figure 5A). In addition, subgroup analysis indicated that
PTH treatment for the duration of 12 months increased the total
hip BMD significantly less than bisphosphonates while higher than
bisphosphonates with a duration of over 12 months (WMD:
21.69, 95% CI: 23.05–0.34, p,0.05, two studies, n=441;
WMD=2.40, 95% CI: 0.49–4.31, P,0.05, three studies, n=242;
respectively). Heterogeneity was not found in either subgroup
(I
2=52.8%, p=0.12; I
2=66.3%, p=0.08, respectively)
(Figure 5B). The shapes of the funnel plots showed symmetry
and the Egger’s test indicated the absence of publication bias
(p=0.14) (plot not shown).
Effects of PTH versus alendronate on BMD of the distal
radius
A significant reduction in distal radius BMD was observed with
PTH as compared to alendronate in the pooled analysis
(WMD=23.68, 95% CI: 25.57–1.79, p,0.01, four studies,
n=422). For the three studies involving women, the pooled effects
presented the same result (WMD=24.38, 95% CI: 26.83–1.93,
p,0.01, n=374). Heterogeneity was found in the above estimates.
For PTH and alendronate treatment in men, data from the study
by Finkelstein et al. [23] showed PTH decreased and alendronate
increased BMD in the distal radius (n=48, p,0.01) (Figure 6A).
For PTH (1–34) treatment, the pooled data showed that PTH (1–
34) significantly reduced BMD in the distal radius as compared to
alendronate (WMD=24.12, 95% CI: 26.69–1.26, p=0.46,
three studies, n=243). The study by Black et al. [10] showed
that distal radius BMD decreased with PTH (1–84) treatment,
while BMD values increased with alendronate treatment (n=179,
p,0.01) (Figure 6B). The funnel plot did not reveal any signs of
symmetry and the Egger’s test indicated the absence of publication
bias (p=0.07) (plot not shown).
Table 2. Effects of PTH versus bisphosphonates on volumetric BMD of the spine.
Author (Ref.) Volumetric BMD of the spine Weight (%)
Weighted mean difference (WMD)
of BMD (95%CI)
PTH bisphosphonates
n percent change(%) n percent change(%)
Finkelstein 2003 [23] 20 48.0627.9 28 3.067.8 24.19 45.00 [32.44, 57.56]
Black 2003 [10] 119 25.3615.1 60 10.368.1 26.78 15.00 [11.60, 18.40]
McClung 2005 [22] 26 19.0617.3 23 3.8616.3 25.35 15.20 [5.79, 24.61]
Finkelstein 2010 [20] 20 61.0631.0 29 1.067.0 23.68 60.00 [46.18, 73.82]
Pooled 185 140 100 32.96 [13.81, 52.12]
Heterogeneity Tau
2 =353.63; Chi
2 =56.19, df =3; I
2 =95%p,0.01
doi:10.1371/journal.pone.0026267.t002
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This meta-analysis revealed that therapy with PTH significantly
increased both area and volumetric lumbar spine BMD as
compared to treatment with bisphosphonates and PTH treatment
induced duration- and dose-dependent increases of hip BMD as
compared to bisphosphonates treatment. This analysis has also
disclosed that for the distal radius, BMD was significantly lower
from PTH treatment than alendronate treatment.
The overall results indicated that PTH therapy displayed higher
gain in areal BMD than therapy with bisphosphonates in respect
to dose and duration of PTH and gender of patients as supported
by the BMD results by volumetric measurements. Previous trials
concerning glucocorticoid-induced osteoporosis displayed similar
results to our analyses. BMD of the lumbar spine had increased
more than 2-fold with PTH (1–34) treatment compared to the
alendronate treatment [27]. A former meta-analysis of pooled anti-
resorptive comparative trials including alendronate showed
significant reductions in PTH treated patients (1–34) for back
pain, which was possibly caused by vertebral fracture [28]. Our
analyses indicated that compared to low does of PTH treatment,
greater BMD gains were obtained with high doses of PTH
compared to treatment with bisphosphonates for the spine
(WMD=8.92 versus WMD=3.31). This finding is in agreement
Figure 4. Assessment of the effects of PTH versus bisphosphonates on BMD of the femoral neck. A: Subgrouped analysis of the dosage
of PTH (1–34) versus bisphosphonates treatment on the femoral neck BMD. B: Subgrouped analysis of the duration of PTH (1–34) versus
bisphosphonates treatment on femoral neck BMD.
doi:10.1371/journal.pone.0026267.g004
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(1–84) [12]. A former meta-analysis also disclosed a dose response
relationship for BMD in the spine with both PTH (1–34) and PTH
(1–84) treatments [30]. Previous placebo-controlled trials showed
that spine BMD was significantly increased after 3 months of PTH
therapy [12,29]. Body et al. [24] revealed that the difference in
Figure 5. Assessment of the effects of PTH versus bisphosphonates on BMD of the total hip. A: Subgrouped analysis of the dosage of PTH
(1–34) versus bisphosphonates treatment on total hip BMD. B: Subgrouped analysis of the duration of PTH (1–34) versus bisphosphonates treatment
on total hip BMD.
doi:10.1371/journal.pone.0026267.g005
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treatment was statistically significant at 3 months. The alendro-
nate-treated women required 12 months of treatment to increase
lumbar spine BMD to a level equilvilant to women treated with
PTH (1–34) for only 3 months.
In contrast to the spine, PTH treatment-induced changes in
BMD of the hip were relatively inconsistent as compared to
treatment with bisphosphonates. The former meta-analysis failed
to draw a conclusion on the effect of PTH compared to
bisphosphonates on hip BMD because of the low number of
studies available [30]. In our meta-analysis, the overall analysis did
not show significant differences between PTH and bisphospho-
nates. Former studies showed a trend towards higher hip BMD
with higher PTH doses in both women and men [9,12,29].
Figure 6. Assessment of the effects of PTH versus bisphosphonates on BMD of the distal radius. A: Subgrouped analysis of PTH versus
bisphosphonates treatment on BMD of the distal radius in women and men. B: Subgrouped analysis of PTH (1–34) and PTH (1–84) versus
bisphosphonates treatment on BMD of the distal radius.
doi:10.1371/journal.pone.0026267.g006
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showed that compared to bisphosphonates, BMD increases of the
femoral neck and total hip were significantly higher with treatment
of high doses (40 mg/day) of PTH (1–34). On the other hand,
analysis on the basis of duration indicated that the effect of PTH
on hip BMD was inferior to bisphosphonates after treatment for
12 months, and was superior for over 12 months. This duration-
related BMD change of PTH versus bisphosphonates could be
explained by the different effects of PTH on trabecular and
cortical bone. In trabecular bone, PTH adds new bone by
increasing active bone remodeling units, which promotes new
bone formation on quiescent bone surfaces. In cortical bone, PTH
stimulates new bone formation mainly on the endocortical surface
and to a lesser extent on the periosteal surface. One of the
potential limitations is that it also increases intracortical (Haver-
sian) remodeling and cortical porosity, thereby decreasing cortical
BMD. Because the hip contains roughly equal amounts of cortical
and trabecular bone, and BMD measured by DXA is a composite
of these two bone types, the effect of PTH treatment on the hip
BMD is the overall result of increased trabecular BMD and
decreased cortical BMD. A transiently increased cortical remod-
eling space may lead to early reduction of cortical BMD. However,
other competing effects within the periosteal, endocortical, and
Haversian systems gradually allow the anabolic effects of PTH to
predominate over the observed effects of an enlarged intracortical
remodeling space. In this scenario, increased hip BMD during the
second year of therapy showed a net gain in BMD.
In our meta-analysis, the distal radius was the only site at which
the pooled data displayed BMD had decreased and was
significantly lower in the PTH group as compared to the
alendronate group. Previous observations disclosed that PTH
therapy reduces BMD of the distal radius [9,29]. On the other
hand, in postmenopausal women, a significant correlation was
observed between changes in percentage from baseline in bone
strength of the ultradistal radius site in the alendronate treated
group [31]. Using animal models, the decrease in areal density
measured by DXA is likely due to increased Haversian
remodeling. As compared to the hip, the distal radius consists
mainly of cortical bone. Increased remodeling transiently increases
cortical porosity, which does not affect biomechanical strength
[32,33]. In Neer’s large placebo-controlled study, PTH therapy
showed no increase in wrist fractures, which was consistent with
the observations of preserved biomechanical strength in animal
models [9].
For the present meta-analysis, most of the data originated from
PTH (1–34) therapy, whereas the amount of data concerning PTH
(1–84) is limited. Former studies showed a convincing reduction of
vertebral fractures in both PTH (1–84) and PTH (1–34) treatment,
but a reduction of non-vertebral fractures was shown in cases of
treatment with PTH (1–34) only [34,35]. No clear conclusions can
be made about the potential differences in effectiveness on BMD
of PTH (1–34) and PTH (1–84) because of the lack of directly
comparative studies. The 100 mg PTH (1–84) trial should
correspond to 43 mg of PTH (1–34) calculated on molecular basis
[34]. We conducted grouped analysis with trials using 40 mgo f
PTH (1–34) and 100 mg PTH (1–84) both on the spine and hip
BMD, but the results displayed large heterogeneity among trials.
Thus, more data are needed on PTH (1–84) to establish if any
clinically significant differences exist between these two types of
PTH agents currently available. In our meta-analysis, dose and
duration of PTH (1–34) was a main source of the heterogeneity. It
was reported that adverse effects were more frequent in the 40 mg
group compared to the 20 mg group [29]. Currently, the dose of
PTH (1–34) approved by the US Food and Drug Administration is
20 mg. Even though BMD increased more with 40 mg for PTH
treatment, fracture rates were similar [9]. Thus, only the lower
dosage is approved for clinical administration. On the other hand,
PTH (1–34) has been associated with the development of
osteosarcoma in experimental animal models [36]; therefore, the
safety of long-term clinical administration of PTH has yet to be
determined. The use of PTH leads to new bone formation, but the
skeletal response wanes over time, thereby limiting its anabolic
effect. Sequential treatment with PTH and bisphosphonate
showed benefits in maintaining gains in BMD [13,37,38].
Certain limitations in the present meta-analysis need to be
addressed. First, the analysis is only based on published data and
no unpublished data were included. Further, heterogeneity of the
patients’ ages and ethnic origin should be expected because it is
impossible to match the cohorts completely for the analyses. On
the other hand, our meta-analysis did not reveal gender-specific
effects between PTH and bisphosphonates on BMD due to the
limited number of trials on men. These factors limit the ability to
elucidate the age-, ethnic- and gender- specific effects of PTH and
bisphosphonates on BMD in osteoporosis treatment. Finally, the
presented analysis was not designed to assess incident fractures.
We conclude that the bone-formation agent PTH substantially
increased BMD of the lumbar spine compared to bisphosphonates
as indicated in the current clinical reports on osteoporosis
treatment. High doses of PTH (1–34) over 12 months of treatment
duration increased BMD in the hip more effectively than
bisphosphonates. PTH treatment reduced BMD of the distal
radius significantly more than alendronate treatment. Further
research could compare the effects of approved doses of PTH to
bisphosphonates on BMD at vital sites in multicentric trials
containing both women and men to attain robust clinical evidence.
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